Peter A. Thompson - Jun 12, 2025 Form 4 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)

Role
Director, 10%+ Owner
Signature
/s/ Leiv Lea, as Attorney-in-Fact for Peter A. Thompson
Stock symbol
CRVS
Transactions as of
Jun 12, 2025
Transactions value $
$0
Form type
4
Date filed
6/16/2025, 04:26 PM
Previous filing
Apr 4, 2025
Next filing
Jun 18, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Thompson Peter A. Director, 10%+ Owner C/O CORVUS PHARMACEUTICALS, INC., 901 GATEWAY BOULEVARD, THIRD FLOOR, SOUTH SAN FRANCISCO /s/ Leiv Lea, as Attorney-in-Fact for Peter A. Thompson 2025-06-16 0001357522

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRVS Stock Option (Right to Buy) Award $0 +15K $0.00 15K Jun 12, 2025 Common Stock 15K $4.24 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
F2 Pursuant to an agreement with OrbiMed Advisors LLC ("Advisors") and OrbiMed Capital GP V LLC ("GP V"), the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to Advisors and GP V, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments V, LP.